NCT03560609 is a NA clinical trial of Ophthalmodynamometer in Keratoconus, sponsored by NYU Langone Health.

Who is sponsoring NCT03560609?

NCT03560609 is sponsored by NYU Langone Health.

What drugs are being tested in NCT03560609?

Interventions in NCT03560609: Ophthalmodynamometer, Goldmann applanation tonometer, Pentacam, ORA, Optical Coherence Tomography (OCT).

What condition does NCT03560609 study?

NCT03560609 studies Keratoconus, Glaucoma.

Is NCT03560609 still recruiting?

NCT03560609 is currently terminated. Last updated 29 January 2025.

Are results published for NCT03560609?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-01-29 · How we verify

NCT03560609

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optic Nerve Head Structural Response to IOP Elevation in Patients With Keratoconus

Terminated NA Results posted Last updated 29 January 2025

What this trial tests

NA trial testing Ophthalmodynamometer in Keratoconus in 3 participants. Terminated before completion.

Timeline

15 November 2018

Primary endpoint
10 February 2023

19 January 2024

Quick facts

Lead sponsor	NYU Langone Health
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	15 November 2018
Primary completion	10 February 2023
Estimated completion	19 January 2024
Sites	1 location across United States

Drugs / interventions tested

Ophthalmodynamometer
Goldmann applanation tonometer
Pentacam
ORA
Optical Coherence Tomography (OCT)

Conditions studied

Keratoconus — all drugs for Keratoconus →
Glaucoma — all drugs for Glaucoma →

Sponsor

NYU Langone Health — full company profile →

Who can join

Adults 18 to 90, any sex, with Keratoconus or Glaucoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The mechanism by which vision loss in glaucoma occurs is still unknown, but it is clear that increased Intraocular Pressure (IOP) is a major risk factor. It is also thought that the lamina cribrosa (LC) is a site of primary damage during the pathogenesis of the disease. The changes caused by intraocular pressure (IOP) modulation at the level of the optic nerve head and LC will be evaluated in the present study. Subjects with keratoconus exhibit abnormal collagen properties that can impair their LC behavior. By evaluating their lamina biomechanical response we can advance our understanding on the role of the lamina in glaucoma pathogenesis. A better understanding of the process will ultimately lead to improved detection and management of glaucoma. It is hypothesized that subjects with keratoconus have an abnormal biomechanical response of the lamina cribrosa in response to IOP modulation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Keratoconus

Currently open trials in the same condition.

NCT07372911 — PRoTECT: Corneal Wavefront Guided PRK + Epi-off CXL vs. PTK+Epi-off CXL in Keratoconus · NA · recruiting
NCT07461129 — Electrophysiological Changes in Cases of Different Stages of Keratoconus · active not recruiting
NCT06601101 — Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus · Phase 3 · recruiting
NCT05516004 — Safety and Effectiveness of the PXL-Platinum 330 System for Cornea Crosslinking in Eyes With Cornea Thinning · Phase 2 · recruiting
NCT06798779 — Predicting Manifest Astigmatism in Keratoconus Patients. · active not recruiting

Other NYU Langone Health trials

Trials by the same sponsor.

NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03560609 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
Last refreshed: 29 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03560609.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing